Rigel Pharmaceuticals, Inc.

301 articles with Rigel Pharmaceuticals, Inc.

• Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)

  6/13/2019

  Rigel Pharmaceuticals, Inc. announced that it will present data on fostamatinib disodium hexahydrate in two posters at the 24th Congress of the European Hematology Association in Amsterdam, The Netherlands, on June 13-16, 2019.

• Rigel to Present at Jefferies 2019 Healthcare Conference

  5/31/2019

  Rigel Pharmaceuticals, Inc. announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2:30pm EDT.

• Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia

  5/16/2019

  Announces resignation of Chief Medical Officer effective August 31, 2019

• Rigel Announces First Quarter 2019 Financial Results and Provides Company Update

  5/7/2019

  Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019, including sales of TAVALISSE®, for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

• Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update

  4/30/2019

  Rigel Pharmaceuticals, Inc. announced that it will report its first quarter 2019 financial results after market close on Tuesday, May 7, 2019.

• Rigel Welcomes Jane Wasman to Board of Directors

  3/26/2019

  Peter S. Ringrose, Ph.D. Retires from Board Position

• Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

  2/28/2019

  Rigel Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

• Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

  2/21/2019

  Rigel Pharmaceuticals, Inc. announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28, 2019.

• Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

  1/23/2019

  Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey

• Rigel Pharmaceuticals Provides Business Update

  1/7/2019

  Reports 1,794 total bottles of TAVALISSE™ (fostamatinib disodium hexahydrate) sold in 2018

• Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:00am PT in San Francisco, CA.

• Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City

  12/5/2018

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

• Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

  11/6/2018

  Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million

• Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition

  11/1/2018

  Data related to fostamatinib accepted for oral presentation and two poster presentations

• Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results

  10/30/2018

  Rigel Pharmaceuticals, Inc. today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6, 2018. 

• Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

  10/29/2018

  Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries.

• Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

  10/11/2018

  First SYK inhibitor for the treatment of adult chronic ITP

• Rigel to Present at the Cantor Global Healthcare Conference

  9/24/2018

  The company's president and chief executive officer is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City on Wednesday, October 3, 2018 at 1:05pm EDT.

• Rigel to Present at the 20th Annual Global Investment Conference in New York City

  8/29/2018

  Rigel Pharmaceuticals, Inc. today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference

• Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

  8/8/2018

  $1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate)